Immediate versus delayed facilitated percutaneous coronary intervention a pilot study

Journal of Cardiovascular Pharmacology

Volumn 46, Issue 1, 2005, Pages 83-88

  Di Pasquale, Pietro ^a,c   Cannizzaro, Sergio ^a   Giambanco, Francesco ^a   Scalzo, Sebastiano ^a   Tricoli, Giuseppe ^a   Fasullo, Sergio ^a   Paterna, Salvatore ^b  

^a Ospedale GF Ingrassia   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c Division of Cardiology Paolo Borsellino   (Italy)

Author keywords

Acute myocardial infarction; Combined therapy; Delayed percutaneous coronary interventions; Facilitated percutaneous coronary interventions; GIIb IIIa inhibitors

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; CLOPIDOGREL; HEPARIN; TICLOPIDINE;

ACUTE HEART INFARCTION; ADULT; ANGIOGRAPHY; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; DELAYED FACILITATED PERCUTANEOUS CORONARY INTERVENTION; DISEASE COURSE; DRUG INFUSION; FEMALE; HEART MUSCLE REPERFUSION; HUMAN; IMMEDIATE PERCUTANEOUS CORONARY INTERVENTION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RESTENOSIS; SAFETY; ST SEGMENT ELEVATION; THROMBOGENESIS; TREATMENT OUTCOME;

ADULT; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; ELECTROCARDIOGRAPHY; ELIGIBILITY DETERMINATION; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION; PATIENT SELECTION; PILOT PROJECTS; PLATELET AGGREGATION INHIBITORS; SURVIVAL RATE; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 21444433018     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000164089.96445.d8     Document Type: Article

References (35)

1. Topol EJ. Current status and future prospects for acute myocardial infarction therapy. Circulation. 2003;108(suppl III):III-6-III-13.
2. Weaver WD, Simes RJ, Betrin A, et al. Comparison of primary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative overview. JAMA. 1997;278:2093-2098.
3. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative overview of 23 randomized trials. Lancet. 2003;361:13-20.
4. Widimsky P, Budesinsky T, Vorac D, et al. Long distance transport for primary angioplasty vs immediate thrombolysis in acute myocardial infarction: final results of the randomized national multicentre trial-PRAGUE-2. Eur Heart J. 2003;24:94-104.
5. Grines CL, Westerhausen DR, Grines LL, et al. A randomized trial of transfer for primary angioplasty versus on-site thrombolysis in high risk myocardial infarction: the Air Primary Angioplasty in Myocardial Infarction study (ARIRPAMI). J Am Coll Cardiol. 2002;39:1713-1719.
6. Andersen HR, Nielsen TT, Rasmussen K, et al. for the DANAMI-2 investigators. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med. 2003;349:733-742.
7. Bonnefoy E, Lapostolle F, Leizorovicz A, et al. on behalf of the Comparison of Angioplasty and prehospital thrombolysis in acute myocardial infarction (CAPTIM) study group. Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomised study. Lancet. 2002;360:825-829.
8. Scheller B, Hennen B, Hammer B, et al. And SIAM III Study Group. Beneficial effects of immediate stenting after thrombolysis in acute myocardial infarction. J Am Coll Cardiol. 2003;42:634-641.
9. Ross AM, Coyne KS, Reiner JS, et al. A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: the PACT trial. J Am Coll Cardiol. 1999;34:1954-1962.
10. Gibson CM. A union in reperfusion: the concept of facilitated percutaneous coronary intervention. J Am Coll Cardiol. 2000;36:1497-1499.
11. Schweiger MG, Cannon PC, Murphy SA, et al. Early coronary intervention following pharmacologic therapy for acute myocardial infarction (the combined TIMI 10B-TIMI14 experience). Am J Cardiol. 2001;88:831-836.
12. Antman EM, Giugliano RP, Gibson CM, et al. for the Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators. Abciximab facilitates the rate and the extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. Circulation. 1999;99:2720-2732.
13. Hermann HC, Moliterno DJ, Ohman EM, et al. Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction: Results from the SPEED (GUSTO-4 Pilot) trial. J Am Coll Cardiol. 2000;36:1489-1496.
14. Fernandez-Aviles F, et al. On behalf of GRACIA-2 investigators. Primary optimal percutaneous coronary intervention versus facilitated intervention (tenecteplase plus stenting) in patients with ST-elevated acute myocardial infarction. Presented to European Society of Cardiology Congress 2003.
15. LeMay MR, Labinaz M, Turek M, et al. Combined Angioplasty and Pharmacological intervention versus thrombolytic alone in acute myocardial infarction (CAPITAL-AMI). Late-Breaking Clinical Trials and Trial Updates: Novel Therapies for Acute Myocardial Infarction. Program and abstract from the American College of Cardiology 53rd annual scientific session; March 7-10: New Orleans, LA.
16. Core JM, Sloan M, Price T, et al. Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the Thrombolysis in Myocardial Infarction Study: Thrombolysis in Myocardial Infarction, phase II, pilot and clinical trial. Circulation. 1991;83:448-459.
17. Sutton AGC, Campbell PG, Graham R, et al. A randomized trial of rescue angioplasty versus a conservative approach for failed fibrinolysis in ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2004;44:287-296.
18. Cannon CP, Gibson CM, Lambrew CT, et al. Relationship of symptom-onset-to-balloon time and door-to balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. JAMA. 2000;283: 2941-2947.
19. Stone GW, Cox D, Garcia E, et al. Normal Flow (T1MI-3) before mechanical reperfusion therapy i san independent determinant of survival in acute myocardial infarction. Circulation. 2001;104:636-641.
20. Cannon CP. Importance of TIMI 3 flow. Circulation. 2001;104: 624-626.
21. Grines CL, Browne KF, Marco J, et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction: the Primary Angioplasty in Myocardial Infarction study group. N Engl J Med. 1993;328:673-679.
22. Nallamothu BK, Bates ER. Percutaneous coronary intervention versus fibrinolytic therapy in acute myocardial infarction: is timing (almost) everything? Am J Cardiol. 2003;92:824-826.
23. Alter DA, Tu JV, Austin PC, et al. Waiting times, revascularization modality, and outcomes after acute myocardial infarction at hospitals with and without on-site revascularization facilities in Canada. J Am Coll Cardiol. 2003;42:410-419.
24. Topol EJ. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet. 2001;357:1905-1914.
25. Fernandez-Aviles F, Alonso JJ, Castro-Beiras A, et al. on behalf of the GRACIA (grupo de analisis de la Cardiopatia isquemica Aguda) Group. Routine invasive strategy within 24 hours of thrombolysis versus ischaemia-guided conservative approach for acute myocardial infarction with ST-segment elevation (GRACIA-I): a randomized controlled trial. Lancet. 2004;364:1045-1053.
26. Zero X. The assessment of the safety and efficacy of a new thrombolytic (ASSENT-3) Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet. 2001; 358:605-613.
27. McKay RG. Evolving strategies in the treatment of acute myocardial infarction in the community hospital setting. J Am Coll Cardiol. 2003;42: 642-645.
28. De Luca G, Sryapranata H, Ottervanger JP, et al. Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction. Circulation. 2004;109:1223-1225.
29. Martines-Rios MA, Rosas M, Gonzales H, et al. for the Sastre Investigators. Comparison of reperfusion regimens with or without tirofiban in ST-elevation acute myocardial infarction. Am J Cardiol. 2004; 93:280-287.
30. Dauermann HL, Sobel BE. Synergistic treatment of ST-segment elevation myocardial infarction with pharmacoinvasive recanalization. J Am Coll Cardiol. 2003;42:646-651.
31. Antman EM, Van de Werf F. Pharmacoinvasive therapy. The future of treatment for ST-Elevation Myocardial infarction. Circulation. 2004;I09: 2480-2486.
32. Johanson P, Wallentin L, Nilsson T, et al. ST-segment analyses and residual thrombi in the infarct-related artery: a report from the ASSENT PLUS ST-monitoring substudy. Am Heart J. 2004;147:853-858.
33. Henriques JP, Haasdijk AP, Zijlstra F on behalf of the Zwolle Myocardial infarction study group. Outcome of primary angioplasty for acute myocardial infarction during routine duty hours versus during off-hours. J Am Coll Cardiol. 2003;41:2138-2142.
34. van't Hof AWJ, De Vries ST, Dambrink JHE, et al. A comparison of two invasive strategies in patients with non-ST elevation acute coronary syndromes: results of the Early or late Intervention in unstable Angina (ELISA) pilot study.2b/3a upstream therapy and acute coronary syndromes. Eur Heart J. 2003;24:1401-1405.
35. Cafri C, Svirsky R, Zelingher J, et al. Improved procedural results in coronary thrombosis are obtained with delayed percutaneous coronary interventions. J Invasive Cardiol. 2004;16:69-71.